CompletedPhase 4

Effect of Tetrabenazine on Stroop Interference in HD

United States2 participantsStarted 2013-03

Plain-language summary

Tetrabenazine has been shown to improve gating of abnormal visual stimuli and improve postural stability in Huntington disease (HD) patients as measured by computerized dynamic posturography testing. This study aims to elucidate whether partial dopaminergic depletion via low dose tetrabenazine has a similar effect on masking out of abnormal visual stimuli on the Stroop interference test.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Established diagnosis of Huntington disease by movement disorders expert * Patients currently taking tetrabenazine. * Patients should not have taken dopamine receptor blocking medication for at least three days Exclusion Criteria: \-

What they're measuring

Change in Stroop Interference Score

Timeframe: 72 hours

Trial details

NCT IDNCT01834911

SponsorNew York Medical College

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-01-01

Results submitted2025-04-09

View on ClinicalTrials.gov More Huntington Disease trials